With this extension the ‘498 patent will now expire 30 June 2023 and the patent is directed to reduced polysaccharide iron oxide complexes, including ferumoxytol.
The ‘498 patent is listed in Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the US Food and Drug Administration (FDA).
USPTO has granted the patent term extension certificate under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984.
The company said that the patent term certificate extends the term of the ‘498 patent from its original expiration date of 2020.
AMAG chief executive officer William Heiden said, "This patent extension for ferumoxytol further lengthens our intellectual property protection and enhances the long-term value of a product that generated 28 percent revenue growth in the U.S. in 2013 for our company."
The company markets Feraheme (ferumoxytol) Injection and MuGard Mucoadhesive Oral Wound Rinse in the US.